These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38697174)

  • 1. Targeting the EGFR signalling pathway in metastatic colorectal cancer.
    Napolitano S; Martini G; Ciardiello D; Del Tufo S; Martinelli E; Troiani T; Ciardiello F
    Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):664-676. PubMed ID: 38697174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.
    Miyamoto Y; Suyama K; Baba H
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired resistance to EGFR-targeted therapies in colorectal cancer.
    Van Emburgh BO; Sartore-Bianchi A; Di Nicolantonio F; Siena S; Bardelli A
    Mol Oncol; 2014 Sep; 8(6):1084-94. PubMed ID: 24913799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
    Efferth T
    Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
    Jeong WJ; Cha PH; Choi KY
    World J Gastroenterol; 2014 Aug; 20(29):9862-71. PubMed ID: 25110417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
    Zhou J; Ji Q; Li Q
    J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
    Sforza V; Martinelli E; Ciardiello F; Gambardella V; Napolitano S; Martini G; Della Corte C; Cardone C; Ferrara ML; Reginelli A; Liguori G; Belli G; Troiani T
    World J Gastroenterol; 2016 Jul; 22(28):6345-61. PubMed ID: 27605871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy.
    González NS; Marchese PV; Baraibar I; Ros J; Salvà F; Rodríguez M; Salvà C; Vaghi C; Alcaraz A; García A; Tabernero J; Élez E
    Expert Opin Investig Drugs; 2024 Jun; 33(6):613-625. PubMed ID: 38775361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
    Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
    Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy in colorectal cancer: current status and future challenges.
    Koutras AK; Starakis I; Kyriakopoulou U; Katsaounis P; Nikolakopoulos A; Kalofonos HP
    Curr Med Chem; 2011; 18(11):1599-612. PubMed ID: 21428886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives.
    Mizukami T; Izawa N; Nakajima TE; Sunakawa Y
    Drugs; 2019 Apr; 79(6):633-645. PubMed ID: 30968289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution.
    Khan K; Valeri N; Dearman C; Rao S; Watkins D; Starling N; Chau I; Cunningham D
    Crit Rev Oncol Hematol; 2019 Nov; 143():153-163. PubMed ID: 31678702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming the hurdles: surmounting acquired resistance to anti-EGFR therapy in metastatic colorectal cancer.
    Sackstein PE; Chintapally N; Wilgucki M; Hartley ML; Alqahtani A; Weinberg BA
    Clin Adv Hematol Oncol; 2023 Nov; 21(11):572-583. PubMed ID: 37948593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer.
    Atkinson CJ; Kawamata F; Liu C; Ham S; Győrffy B; Munn AL; Wei MQ; Möller A; Whitehall V; Wiegmans AP
    Mol Oncol; 2019 Apr; 13(4):725-737. PubMed ID: 30478887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
    Porru M; Pompili L; Caruso C; Biroccio A; Leonetti C
    J Exp Clin Cancer Res; 2018 Mar; 37(1):57. PubMed ID: 29534749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
    Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
    J Natl Cancer Inst; 2009 Oct; 101(19):1308-24. PubMed ID: 19738166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Amatu A; Porcu L; Ghezzi S; Lonardi S; Leone F; Bergamo F; Fenocchio E; Martinelli E; Borelli B; Tosi F; Racca P; Valtorta E; Bonoldi E; Martino C; Vaghi C; Marrapese G; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Torri V; Marsoni S; Siena S
    Oncologist; 2019 Oct; 24(10):1395-1402. PubMed ID: 30952821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer.
    Jones J; Ciombor K; Wu C; Bekaii-Saab T; Strickler J
    Oncology (Williston Park); 2021 Oct; 35(10):654-660. PubMed ID: 34677922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
    Vangala D; Ladigan S; Liffers ST; Noseir S; Maghnouj A; Götze TM; Verdoodt B; Klein-Scory S; Godfrey L; Zowada MK; Huerta M; Edelstein DL; de Villarreal JM; Marqués M; Kumbrink J; Jung A; Schiergens T; Werner J; Heinemann V; Stintzing S; Lindoerfer D; Mansmann U; Pohl M; Teschendorf C; Bernhardt C; Wolters H; Stern J; Usta S; Viebahn R; Admard J; Casadei N; Fröhling S; Ball CR; Siveke JT; Glimm H; Tannapfel A; Schmiegel W; Hahn SA
    Genome Med; 2021 Jul; 13(1):116. PubMed ID: 34271981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.